As the NANOG–HSP90A axis has been implicated as a central channel in the development of immune-resistant phenotypes, we believe that inhibition of HSP90A may be an effective strategy to control immune-refractory tumor cells. The gene discussed is HSP90AA1; the disease is neoplasm.